开放腹主动脉瘤修复中ACT引导肝素化与单次肝素推注的成本效用分析
ACT组6个月总医疗成本更高但差异无统计学意义,QoL较低,成本效用比为负值。
要点
- ACT引导肝素化未改善患者结局,6个月QoL更低。
核心结论
- ACT引导肝素化未改善患者结局,6个月QoL更低且成本效用为负。
主要发现
- 6个月QALYs ACT组0.365(95%CI 0.345-0.385),对照组0.395(95%CI 0.375-0.415),差异0.030(95%CI 0.002-0.059)。
临床怎么用
- 开放腹主动脉瘤修复中ACT引导肝素化未显示结局或成本效用优势。
局限性
- 试验因无效提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a health and economic evaluation of different heparinisation strategies during elective open abdominal aortic aneurysm repair. METHODS: Costs were derived from the Dutch National Health Institute, the Dutch Pharmacotherapeutic Registry, and the local hospital ledger. Quality of life (QoL) was assessed using the EuroQol-5-dimension-5-level questionnaire at baseline and at one week, and one, three, and six months after the operation. Resource utilisation data were obtained through the Medical Consumption Questionnaire and the Productivity Cost Questionnaire. RESULTS: Two hundred and ninety-four patients were included; of these, 149 received activated clotting time (ACT) guided heparinisation and 145 received a single bolus of 5 000 IU of heparin. Total healthcare costs at six months were €3 035 313 for the ACT guided group (n = 149) compared with €2 627 682 for the control group (n = 145). The mean total costs per patient were €20 371 (95% confidence interval [CI] 17 090 - 23 653) in the ACT guided group and €18 122 (95% CI 14 849 - 21 395) in the control group (mean difference per patient €2 249, 95% CI -2 370 - 6 868, p = .34). Mean quality adjusted life years over six months was 0.365 (95% CI 0.345 - 0.385) in the ACT group and 0.395 (95% CI 0.375 - 0.415) in the control group (difference 0.030, 95% CI 0.002 - 0.059). QoL at six months was lower in the ACT group (p = .037). Incremental cost utility and cost effectiveness ratios were -€74 664 (95% bias corrected and accelerated CI -444 389 - 195 579) and €83 354 (95% bias corrected and accelerated CI -471 353 - 651 004), respectively. CONCLUSION: In the Activated Clotting Time Guided Heparinisation during Open Abdominal Aortic Aneurysm Repair trial, which was terminated early owing to futility, ACT guided heparinisation did not improve patient outcomes and resulted in a lower QoL at six months, along with negative cost utility.
引用
- Steunenberg TAH, van Dieren S, Wiersema AM, et al. Quality of Life, Cost Effectiveness, and Cost Utility Analysis of Activated Clotting Time Guided Heparinisation vs. a Single Bolus of Heparin in Open Abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2026. PMID: 41520771. doi:10.1016/j.ejvs.2026.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。